Intravitreal bevacizumab injection for retinopathy of prematurity and pulmonary hypertension

J Perinatol. 2023 Feb;43(2):236-237. doi: 10.1038/s41372-022-01489-0. Epub 2022 Aug 15.

Authors

Lidia Park¹, Lee Donohue², Satyan Lakshminrusimha², Deepika Sankaran³

Affiliations

¹ Department of Pediatrics, University of California, Davis, Sacramento, CA, USA.
² Division of Neonatology, Department of Pediatrics, University of California, Davis, Sacramento, CA, USA.
³ Division of Neonatology, Department of Pediatrics, University of California, Davis, Sacramento, CA, USA. dsankaran@ucdavis.edu.

PMID: 35970854
DOI: 10.1038/s41372-022-01489-0

No abstract available

Publication types

Research Support, N.I.H., Extramural
Research Support, Non-U.S. Gov't

MeSH terms

Angiogenesis Inhibitors / therapeutic use
Bevacizumab / therapeutic use
Gestational Age
Humans
Hypertension, Pulmonary* / drug therapy
Infant, Newborn
Infant, Premature
Intravitreal Injections
Retinopathy of Prematurity* / drug therapy

Substances

Bevacizumab
Angiogenesis Inhibitors

Grants and funding